Metraipolis › archive › dc_fa427d1411e2

First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review — Europe PMC PMID:41595254

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41595254
DOI
10.3390/cancers18020335
License (as archived)
solo-consultazione
Archived
2026-11-06T15:29:28.136Z
SHA-256 of the archived text
6899c4bca25393a488ecff9d70c5b66e543f95613e887094cf98c6b11816b1f1
Stable URL of this page
https://metraipolis.com/documento/dc_fa427d1411e2

How to cite

First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review — Europe PMC PMID:41595254 — Europe PMC (en), https://europepmc.org/article/MED/41595254 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fa427d1411e2 (Metraipolis archive dc_fa427d1411e2, sha256 6899c4bca25393a488ecff9d70c5b66e543f95613e887094cf98c6b11816b1f1)
BibTeX
@misc{dcfa427d1411e2,
  title = {First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review — Europe PMC PMID:41595254},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41595254},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fa427d1411e2; sha256 6899c4bca25393a488ecff9d70c5b66e543f95613e887094cf98c6b11816b1f1},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41595254. Agents can read the archived copy with the MCP tool read_document.